

Press Release

Prescriptions of medical cannabis dried flowers have started for patients included in the French pilot programme

St-Cloud, France, 25th August 2021 – The prescriptions of cannabis flowers to patients have started in France. The first batches provided by Aurora and distributed by Ethypharm are now available to the healthcare professionals, formally trained, of the first-ever French pilot program. Early 2021, Ethypharm and Aurora Europe announced their selection by the National Agency for the Safety of Medicines and Health Products (ANSM) as sole primary suppliers in the categories of medical cannabis dried flowers. Under the terms of the exclusive partnership, Aurora supplies the products and Ethypharm's French subsidiary, Laboratoires Ethypharm, is responsible for pharmaceutical distribution.

In a decree dated 7 October 2020, French authorities set the framework for a two-year pilot program of medical cannabis in France, which started earlier in 2021. Ethypharm and Aurora Europe were amongst the six producer-and-distributor tandems selected to provide medical cannabis products. They were nominated as the primary supplier for all the three lots they applied for (out of nine awarded) which are: Aurora 20/1 XPE (high-THC dried flowers), Aurora 8/8 XPE (THC: CBD balanced dried flowers) and Aurora 1/12 XPE (high-CBD dried flowers). Dried flowers are to be administered with a vaporizer by STORZ & BICKEL, a well-known product tested and used by patients across Europe, recently selected by the ANSM. This solution was particularly expected to complement the other medical cannabis forms already made available in the pilot. With that solution in place, the Ethypharm-Aurora tandem is now able to provide the entire supply of medical cannabis dried flowers to French patients during the pilot program.

Collaboration and partnerships are indeed part of Ethypharm's DNA. By looking for the optimal partner in any country or region of the world, Ethypharm develops new ways to provide patients with the medical treatment they need. *"Combining our pharmaceutical skills is, in our view, the right approach to build trust and confidence in medical cannabis for the long term in France. We want to be a driving force to support patients suffering from chronic pain when there is no other therapeutic option than medical cannabis. We are building the same type of cooperation in Germany with our partner Clever Leaves"* declared Jean Monin, Chief Commercial Operations Officer of Ethypharm. *"With its deep expertise in Central Nervous System disorders and experience in highly regulated medicines, Ethypharm is well prepared to collaborate with health authorities and physicians. If the pilot is positive, Ethypharm will, as a pharmaceutical company, secure distribution and access for the patient to the new option of therapeutic cannabis."*

The first batches of the three types of pharmaceutical quality pharmaceutical-grade medical cannabis dried flowers (THC dominant, balanced and CBD dominant) were delivered a few weeks ago to the French authorities. Aurora Nordic, production facility in Odense, Denmark Aurora's European Good Manufacturing Practices EU-GMP certified by Danish Health

Authorities, is committed to providing sufficient and consistent supply to patients and healthcare professionals as part of the pilot program. Up to 3,000 patients will benefit from the two-year trial led by ANSM.

"Aurora's participation in the French pilot program is a significant step toward providing better access to patients and will support the destigmatization of medical cannabis in France," says Dr. Axel Gille, President of Aurora Europe. "Aurora has a proven track record of supporting the advancement of international medical cannabis markets alongside government bodies and with a deep commitment to compliance and excellence in the large-scale production of high-quality pharmaceutical grade medical cannabis. If successful, this pilot program could lead to one of the largest regulated markets for medical cannabis in Europe."

About Aurora Europe

Aurora Europe, headquartered in Berlin, Germany, is a subsidiary of Aurora Cannabis Inc., a global leader in the cannabis industry serving both medical and consumer markets and dedicated to helping people improve their lives. Aurora Europe supplies pharmaceutical quality medical cannabis products to patients throughout Europe. In 2015, Aurora entered the market in Europe and today operates as one of the largest authorised producers and distributors of medical cannabis in Europe. Aurora's internal network of EU GMP facilities continues to bring pharmaceutical quality, premium medical cannabis to patients worldwide, at the forefront in Europe with its facility Aurora Nordic in Odense, Denmark.

For more information visit www.auroramedicine.com and follow us on [LinkedIn](#).

About Ethypharm

Ethypharm is a European pharmaceutical company focused on two therapeutic areas: the Central Nervous System and Critical Care. Ethypharm markets its drugs directly in Europe and China, and with partners in North America and the Middle East where its drugs are in high demand. The Group employs more than 1,500 people, mainly in Europe and China. Ethypharm works closely with authorities and healthcare professionals to ensure the appropriate use of and access to its medicines, by as many people as possible.

For more information, visit www.ethypharm.com and follow us on [LinkedIn](#).

Media Relations

Mai Tran, presse@ethypharm.com, + 33 (0) 6 64 74 70 80